Cayman Chemical

A post-synaptic α1-adrenergic receptor antagonist commonly used to improve lower urinary tract symptoms associated with benign prostatic hyperplasia; displays high-affinity with non-selectivity for the three known human α1 adrenoceptors (pKi = 8.0, 8.0, and 8.5 for α1A, α1B,...

Molecular Formula C₁₉H₂₂N₂O₃S • C₂H₂O₄ Formula Weight 448.5

An anti-protozoal agent; prevents misfolding of prion protein (EC₅₀ = 0.3 μM), blocks voltage-dependent sodium channels (IC₅₀ = 3.3 μM), inhibits aldehyde oxidase (IC₅₀ = 3.3 μM), antagonizes the riboflavin-binding protein (Ki = 6.7 μM), inhibits...

An ATP-competitive inhibitor of Hsp90 that causes degradation of client proteins, resulting in cell cycle arrest or apoptosis; orally bioavailable and shows efficacy in tumor regression in gastric carcinoma and melanoma xenografts in mice.

The first described limonoid, a group of compounds known to impart bitter flavor in citrus fruits; reported to demonstrate anti-proliferative and proapoptotic activity on several cancer cell lines as well as pesticidal, anti-malarial, anti-microbial, and anti-HIV activity.

An ω-6 isomer of docosapentaenoic acid formed by the elongation and desaturation of arachidonic acid; diminished during fatty acid desaturase syndrome and increased in nonalcoholic steatohepatitis.

A lipid peroxidation product derived from oxidized ω-3 fatty acids such as DHA.

15(R)-PGE1 is the “unnatural” C-15 stereoisomer of PGE1. It is essentially inactive biologically when compared to PGE1. It is a non-competitive inhibitor of 15-hydroxy PGDH with an IC₅₀ of 189 µM.

Antigen: purified human recombinant sPLA2 (type V), W79A mutant Host: mouse Cross-Reactivity: (+) human sPLA2 (type V); (−) human sPLA2 (type IIa) and cPLA2 Application(s): ELISA, IHC (formalin-fixed paraffin-embedded tissue), and WB Isotype: IgG1 Clone designation: MCL-3G1

A selective inhibitor of p110α with an IC50 value of 5.8 nM; inhibits p110γ and p110β with IC50 values of 0.076 µM and 1.3 µM, respectively.

A photoreversible covalent inhibitor of PTPs; binds the catalytic domain of SHP-1 (Ki = 184 µM) and covalently reacts with free thiols, a reaction that is reversible with irradiation (350 nm).

CAS Number: 1355326-21-4 Molecular Formula: C₃₀H₃₁FN₄O₂ Formula Weight: 498.6

A selective GPR55 inverse agonist that antagonizes GPR55 constitutive activity (IC₅₀ = 15 μM); blocks GPR55-mediated endothelial wound healing and reverses LPI-inhibited platelet aggregation.

An H2 receptor antagonist (Ki = 0.6 µM) that competitively inhibits the binding of histamine to H2 receptors, thereby reducing both intracellular cAMP concentrations and acid secretion by parietal cells.

A luminescent probe (absorption λmax: 455 nm, luminescence λmax: 613 nm) widely used for detection and quantitation of oxygen; strongly reduced by molecular oxygen as a result of dynamic quenching; thus oxygen detection can be based on either measurement of intensity or decay time.

Complex IV (cytochrome c oxidase) is the terminal electron acceptor in the mitochondrial electron transport chain. Complex IV functions by oxidizing cytochrome c and completing a four electron reduction of oxygen (O2) to form water. During this process, two H+ are translocated from the mitochondrial...

A β-adrenergic receptor agonist that putatively through activation of protein kinase A increases protein synthesis in skeletal muscle fibers, as well as reduces lipogenesis and increases lipolysis in adipose tissues; used as a veterinary food additive to increase lean body weight in commercial...

The active form of NMU in humans; binds with high affinity to receptors on human left ventricle and coronary artery (KDs = 0.26 and 0.11 nM, respectively), eliciting endothelium-independent vasoconstriction; suppresses glucose-stimulated insulin secretion in human islets.

(±)11-HEDE is produced by non-enzymatic oxidation of 11,14-eicosadienoic acid. The biological activity of (±)11-HEDE has not been clearly documented.

A nitro group-containing blebbistatin analog with the same stereochemistry as the inactive enantiomer, (+)-blebbistatin.

A SIRT1-specific inhibitor (IC50 = 15 μM); inhibits metastatic breast cancer MDA-MB 231 cell proliferation (IC50 = 512 nM), dose-dependently increasing p53 acetylation and p53-mediated apoptosis in these cells.

An ester version of the free acid which may be more suitable for the formulation of fatty acid-containing diets and dietary supplements.

Inhibitor of NF-κB activation that blocks the phosphorylation of IKK and IκB (IC50 ~ 40 μM); dose dependently inhibits the expression and secretion of IL-6, IL-8, and MCP-1 in human aortic endothelial cells.

An internal standard for the quantification of OEA by GC- or LC-MS.